Home Breast Cancer HER2+

HER2+

Trastuzumab Deruxtecan Offers an Effective Treatment Option for Patients with Difficult-to-treat HER2-expressing Solid Tumors

ADC Review | Editorial Team

Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

FDA Accepts for Priority Review of sBLA for Gilead’s Sacituzumab Govitecan for Pre-Treated HR+/HER2- Metastatic Breast Cancer

General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

What to Expect at ESMO 2022: Sacituzumab Govitecan Show PFS Benefits in Patients Diagnosed with HR+/HER2- MBC

Following Positive Results of Phase III TULIP Trial: FDA Accepts Byondis’ BLA for [Vic-] Trastuzumab Duocarmazine in HER2+ mBC

ESMO 2017 - 3

Trastuzumab Deruxtecan Receives Breakthrough Therapy Designation for HER2+ Metastatic Breast Cancer in Patients Treated with One or More Prior Anti-HER2-Based Regimens

Chinese Regulator Conditionally Approves Disitamab Vedotin in Advanced or Metastatic Gastric Cancer

By

ADC Review | Editorial Team

-

Disitamab vedotin (爱地希®/Aidixi®; Previously known as RC48; Remegen Biosciences) has been granted conditional marketing approval by the National Medical...